See more : Telecanor Global Limited (TELECANOR.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Poolbeg Pharma PLC (POLBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poolbeg Pharma PLC, a leading company in the Biotechnology industry within the Healthcare sector.
- Joint Stock Company Kaspi.kz (KKS.F) Income Statement Analysis – Financial Results
- Medicskin Holdings Limited (8307.HK) Income Statement Analysis – Financial Results
- Seazen Group Limited (1030.HK) Income Statement Analysis – Financial Results
- Veeva Systems Inc. (VEEV) Income Statement Analysis – Financial Results
- Trakcja S.A. (TRK.WA) Income Statement Analysis – Financial Results
Poolbeg Pharma PLC (POLBF)
About Poolbeg Pharma PLC
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 26.00K | 26.00K | 18.00K |
| Gross Profit | -26.00K | -26.00K | -18.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.68M | 2.20M | 414.00K |
| General & Administrative | 3.38M | 3.06M | 2.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 3.38M | 3.06M | 2.03M |
| Other Expenses | -26.00K | 0.00 | 0.00 |
| Operating Expenses | 5.04M | 4.99M | 2.34M |
| Cost & Expenses | 5.04M | 4.99M | 2.34M |
| Interest Income | 0.00 | 209.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 26.00K | 26.00K | 18.00K |
| EBITDA | -4.66M | -4.96M | -3.09M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.69M | -4.99M | -2.34M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 181.00K | 209.00K | 0.00 |
| Income Before Tax | -4.51M | -4.78M | -2.34M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 574.00K | -91.00K | 42.00K |
| Net Income | -3.93M | -4.69M | -2.34M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -9.37 | -0.01 |
| EPS Diluted | -0.01 | -9.37 | -0.01 |
| Weighted Avg Shares Out | 497.59M | 500.00K | 317.23M |
| Weighted Avg Shares Out (Dil) | 500.00M | 500.00K | 317.23M |
Poolbeg Pharma signs exclusive deal with University College Dublin for vaccine candidate
Poolbeg Pharma PLC Announces HC Wainwright Global Investment Conference
Poolbeg Pharma has made significant progress, says upbeat City broker
Poolbeg Pharma eyes busy second half as value inflexion point nears
Poolbeg Pharma describes as 'major milestone' the green light for flu drug trial
Poolbeg Pharma partner completes AI model using RSV challenge trial data
Poolbeg Pharma hails US patent office success; says it marks an important step towards commercialising assets
Poolbeg Pharma appoints a drug manufacturer ahead of its flu trial next month
Poolbeg Pharma receives European patent protection for key asset
Poolbeg Pharma says share sale will widen the investor base and increase future liquidity
Source: https://incomestatements.info
Category: Stock Reports